The proportion of pre-MN participants harboring CH driver mutations was similar among pre-AML (126/372 = 33.9%), pre-MDS (179/544 = 32.9%) and pre-MPN (210/892 = 23.5%) cases. The gene discussed is C4B; the disease is myeloproliferative neoplasm.